% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kebir:810072,
author = {Kebir, S. and Fimmers, R. and Galldiks, N. and Scha fer,
N. and Mack, F. and Schaub, C. and Stuplich, M. and Niessen,
M. and Tzaridis, T. and Simon, M. and Stoffels, G. and
Langen, K.-J. and Scheffler, B. and Glas, M. and Herrlinger,
U.},
title = {{L}ate {P}seudoprogression in {G}lioblastoma: {D}iagnostic
{V}alue of {D}ynamic
{O}-(2-[$^{18}${F}]fluoroethyl)-{L}-{T}yrosine {PET}},
journal = {Clinical cancer research},
volume = {22},
number = {9},
issn = {1557-3265},
address = {Philadelphia, Pa. [u.a.]},
publisher = {AACR},
reportid = {FZJ-2016-02953},
pages = {2190 - 2196},
year = {2016},
abstract = {Purpose: Pseudoprogression (PsP) is characterized by
therapy-associated but not tumor growth–associated
increases of contrast-enhancing glioblastoma lesions on MRI.
Although typically occurring during the first 3 months after
radiochemotherapy, PsP may occur later in the course of the
disease and may then be particularly difficult to
distinguish from true tumor progression. We explored PET
using O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET-PET) to
approach the diagnostic dilemma.Experimental Design:
Twenty-six patients with glioblastoma that presented with
increasing contrast-enhancing lesions later than 3 months
after completion of radiochemotherapy underwent
18F-FET–PET. Maximum and mean tumor/brain ratios (TBRmax
and TBRmean) of 18F-FET uptake as well as time-to-peak (TTP)
and patterns of the time-activity curves were determined.
The final diagnosis of true progression versus late PsP was
based on follow-up MRI using RANO criteria.Results: Late PsP
occurred in 7 patients with a median time from
radiochemotherapy completion of 24 weeks while the remaining
patients showed true tumor progression. TBRmax and TBRmean
were significantly higher in patients with true progression
than in patients with late PsP (TBRmax 2.4 ± 0.1 vs. 1.5 ±
0.2, P = 0.003; TBRmean 2.1 ± 0.1 vs. 1.5 ± 0.2, P =
0.012) whereas TTP was significantly shorter (mean TTP 25 ±
2 vs. 40 ± 2 min, P < 0.001). ROC analysis yielded an
optimal cutoff value of 1.9 for TBRmax to differentiate
between true progression and late PsP (sensitivity $84\%,$
specificity $86\%,$ accuracy $85\%,$ P = 0.015).Conclusions:
O-(2-[18F]fluoroethyl)-L-tyrosine PET provides valuable
information in assessing the elusive phenomenon of late PsP.
Clin Cancer Res; 22(9); 2190–6. ©2015 AACR.},
cin = {INM-3 / INM-4 / IKP-4 / JARA-BRAIN},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
I:(DE-Juel1)IKP-4-20111104 / $I:(DE-82)080010_20140620$},
pnm = {573 - Neuroimaging (POF3-573)},
pid = {G:(DE-HGF)POF3-573},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000375329100015},
pubmed = {pmid:26673798},
doi = {10.1158/1078-0432.CCR-15-1334},
url = {https://juser.fz-juelich.de/record/810072},
}